STOCK TITAN
  1. Home
  2. News
  3. OCUL

Ocular Therapeutix, Inc. - OCUL STOCK NEWS

Welcome to our dedicated page for Ocular Therapeutix news (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeutix stock.

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company dedicated to enhancing vision and quality of life through the development, manufacturing, and commercialization of innovative ocular therapies. The company employs its proprietary hydrogel-based formulation technology to address various diseases and conditions affecting the eye.

The company's lead product, DEXTENZA® (dexamethasone insert), an FDA-approved corticosteroid, is designed for intracanalicular use to treat ocular inflammation and pain following ophthalmic surgery and ocular itching due to allergic conjunctivitis. DEXTENZA delivers dexamethasone to the ocular surface for up to 30 days without preservatives, resorbing naturally, eliminating the need for removal.

Ocular Therapeutix’s pipeline includes several promising candidates. OTX-TIC (travoprost intracameral implant) is in Phase 2 trials for treating open-angle glaucoma and ocular hypertension. Another key candidate is AXPAXLI™ (axitinib intravitreal implant), currently in Phase 3 trials for wet age-related macular degeneration (AMD) and Phase 1 trials for non-proliferative diabetic retinopathy (DR). The company also has OTX-CSI (cyclosporine intracanalicular insert) and OTX-DED (dexamethasone intracanalicular insert) for dry eye disease.

Recently, Ocular Therapeutix announced positive Phase 1 results for AXPAXLI in diabetic retinopathy, accelerating its development to Phase 3. Moreover, recent strategic changes include the appointment of Dr. Pravin U. Dugel as the CEO, aiming to transform the company into a leading retina-focused biopharmaceutical entity.

Ocular Therapeutix has secured significant partnerships and funding to support the clinical development of its robust pipeline. These include a licensing agreement with AffaMed Therapeutics for the commercialization of DEXTENZA in Greater China and ASEAN markets.

Follow Ocular Therapeutix for the latest updates on their innovative pipeline and corporate developments via their website, LinkedIn, and Twitter.

News

Ocular Therapeutix™ Announces Board of Directors and Leadership Updates

Rhea-AI Summary
Ocular Therapeutix, Inc. announces significant leadership updates with industry expert Pravin U. Dugel, MD appointed as Executive Chair. Jeffrey S. Heier, MD becomes Chief Scientific Officer, Peter K. Kaiser, MD as Medical Director, and Sanjay Nayak, MBBS, PhD as Chief Strategy Officer. The company aims to become a leader in retina care with a focus on wet AMD programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.99%
Tags
management
-
News

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis

Rhea-AI Summary
AffaMed Therapeutics announces acceptance of DEXTENZA NDA by Singapore Health Sciences Authority for treating ocular inflammation and pain following ophthalmic surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer

Rhea-AI Summary
Ocular Therapeutix, Inc. appoints Steve Meyers as Chief Commercial Officer, showcasing dedication to expanding their drug portfolio for eye-related conditions. Meyers brings over 20 years of commercial experience to drive Ocular's commercial efforts forward.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.19%
Tags
management
News

Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

Rhea-AI Summary
Ocular Therapeutix, Inc. announces the initiation of Phase 3 SOL-1 clinical trial for AXPAXLI in wet age-related macular degeneration (AMD). The trial aims to evaluate the efficacy and safety of the treatment, potentially reducing the need for frequent injections and office visits for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.42%
Tags
clinical trial
-
News

Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

Rhea-AI Summary
Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced that the U.S. FDA has agreed to a Special Protocol Assessment (SPA) Agreement Modification for the Company’s pivotal Phase 3 SOL clinical trial of AXPAXLI™ for the treatment of wet age-related macular degeneration (wet AMD). The amendment expands eligibility criteria, allowing treatment-naïve wet AMD subjects with visual acuity of approximately 20/80 or better to enroll in the trial. The modification also permits the trial to move forward with a single optimized implant with a drug load of 450 µg of a more soluble form of axitinib, aimed at accelerating the enrollment process and improving drug release synchronization with hydrogel bioresorption.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.98%
Tags
clinical trial
-
News

Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Rhea-AI Summary
Ocular Therapeutix, Inc. (Nasdaq: OCUL) closed a public offering of 35,420,000 shares of its common stock at a price of $3.25 per share, generating approximately $115.1 million in gross proceeds. The company plans to use the net proceeds for the Phase 3 clinical development of AXPAXLI for the treatment of wet AMD and other clinical development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.23%
Tags
offering
News

Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock

Rhea-AI Summary
Ocular Therapeutix™, Inc. (Nasdaq: OCUL) announced the pricing of an underwritten public offering of 30,800,000 shares of its common stock at a public offering price of $3.25 per share for gross proceeds of $100.1 million. The Company has also granted the underwriters a 30-day option to purchase up to an additional 4,620,000 shares. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
offering
-
News

Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock

Rhea-AI Summary
Ocular Therapeutix, Inc. (OCUL) has commenced an underwritten public offering of its common stock, with an option for underwriters to purchase additional shares. The company plans to use the proceeds to fund the Phase 3 clinical development of AXPAXLI for the treatment of wet AMD and support other clinical development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
offering
-
News

Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

Rhea-AI Summary
Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced its participation in upcoming healthcare conferences including Jefferies London Healthcare Conference, BTIG 3rd Annual Ophthalmology Day, and Piper Sandler 35th Annual Healthcare Conference. Management will be available for investor meetings, and live webcasts of the fireside chats will be accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.2%
Tags
conferences
News

Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update

Rhea-AI Summary
OCUL: FDA agrees to pivotal trial design for AXPAXLI in wet AMD and non-proliferative diabetic retinopathy. Q3 2023 DEXTENZA revenue grows 26% to $15.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.2%
Tags
earnings

FAQ

What is the current stock price of Ocular Therapeutix (OCUL)?

The current stock price of Ocular Therapeutix (OCUL) is $9.089 as of January 7, 2025.

What is the market cap of Ocular Therapeutix (OCUL)?

The market cap of Ocular Therapeutix (OCUL) is approximately 1.4B.

What is Ocular Therapeutix’s main technology platform?

Ocular Therapeutix uses a proprietary hydrogel-based formulation technology for delivering therapeutic agents to the eye.

What is DEXTENZA® used for?

DEXTENZA® is used for treating ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis.

Which product is Ocular Therapeutix developing for open-angle glaucoma?

Ocular Therapeutix is developing OTX-TIC (travoprost intracameral implant) for the treatment of open-angle glaucoma and ocular hypertension.

What is the status of AXPAXLI™ (OTX-TKI)?

AXPAXLI™ (OTX-TKI) is currently in Phase 3 clinical trials for wet AMD and Phase 1 trials for non-proliferative diabetic retinopathy.

Who is the current CEO of Ocular Therapeutix?

Dr. Pravin U. Dugel is the current President and CEO of Ocular Therapeutix.

What recent partnerships has Ocular Therapeutix secured?

Ocular Therapeutix has a licensing agreement with AffaMed Therapeutics for the commercialization of DEXTENZA in Greater China and ASEAN markets.

What are OTX-CSI and OTX-DED?

OTX-CSI is a cyclosporine intracanalicular insert for the chronic treatment of dry eye disease. OTX-DED is a dexamethasone intracanalicular insert for the short-term treatment of dry eye symptoms.

How long does DEXTENZA deliver medication?

DEXTENZA delivers dexamethasone to the ocular surface for up to 30 days without the need for preservatives or removal.

What clinical trial results were recently announced for AXPAXLI?

Ocular Therapeutix announced positive topline results from the Phase 1 HELIOS study for AXPAXLI in non-proliferative diabetic retinopathy.

What is the focus of Ocular Therapeutix?

Ocular Therapeutix focuses on developing innovative therapies for ocular diseases, including wet AMD, diabetic retinopathy, open-angle glaucoma, and dry eye disease.
Stock OCUL logo
Ocular Therapeutix, Inc.

Nasdaq:OCUL

OCUL Rankings

#2274 Ranked by Market Cap
N/A Ranked by Dividends

OCUL Stock Data

1.40B
151.33M
1.06%
91.08%
8.13%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BEDFORD